Creditos
Bus.Valor
Conectar
Bus.User
Desde:
30/01/2021
OFF:
30 Min
Buenas noches. Al final hemos superado los 90... Mejor subir poco a poco muy alto que subida vertical para caída igual de vertical. Yo creo que está vez si que llegaremos lejos. Hoy he pillado mi último bocadito de acciones de Pharmamar (20 a 89€) y ya me quedo quietecito con las 250 acciones que tengo... Cuando lleguemos a 140€ no se que haré con ellas, pero está vez no quiero que me pille la bajada....
0
La red social X está echando chispas ahora mismo con la lurbi
(2)
0
Mensaje de: Mininversor Hora: 02/06/2025 23:59:43
This is the first phase 3 study to show a progression-free and overall survivial improvement with first-line maintenance in extensive stage SCLC and the result is likely to be practice-changing, establishing a new standard of care in this tough-to-treat disease.
(3)
2
Mensaje de: Mininversor Hora: 02/06/2025 23:59:43
The primary endpoints of the study were progression-free and overall survival. Four hundred and eighty-three patients were randomized and at a median follow-up of 15 months, the median progression-free survival for patients who received the combination was 5.4 months and the median overall survival was 13.2 months. This compares with 2.1 and 10.6 months, respectively, in patients who received atezolizumab only. The lurbinectedin and atezolizumab combination was generally well-tolerated, with no new or unexpected safety signals. The benefit was consistent in magnitude across all the relevant patient subgroups.
(2)
2
The IMforte (
https://meetings.asco.org/abstracts-p
...) trial is a global, randomized trial in which patients are initially treated with atezolizumab, and those patients who do not progress on induction therapy are then randomized to maintenance therapy with atezolizumab alone or atezolizumab with lurbinectedin.(3)
0
Mensaje de: Mininversor Hora: 02/06/2025 23:58:37
Despite some improvements in the first-line treatment of extensive small cell lung cancer with the use of checkpoint inhibitors in combination with platinum-based chemotherapy, most of the patients experience early disease progression and long-term survival remains very limited. This provides a rationale for considering a maintenance intervention. Lurbinectedin is an alkylating agent and transcription inhibitor that is already approved in the United States for patients with relapsed/refractory metastatic SCLC following platinum-based chemotherapy. It has been shown to synergize with immune checkpoint inhibitors in pre-clinical studies and has also been evaluated in early-phase clinical trials.
(2)
2
Today’s selection features reports of 3 randomized trials in very different clinical settings: maintenance therapy in extensive small cell lung cancer (SCLC), upfront surgery in advanced ovarian cancer, and a supportive care intervention for patients undergoing hematopoietic stem cell transplantation.
The first of these studies, Abstract 8006 (
The first of these studies, Abstract 8006 (
https://meetings.asco.org/abstracts-p
...) , was presented by Dr. Luis Paz-Ares from the University Hospital October 12 in Madrid, Spain, and reports the primary results of the IMforte (https://meetings.asco.org/abstracts-p
...) trial. This was a phase 3 trial evaluating the combination of lurbinectedin and atezolizumab as first-line maintenance therapy in patients with extensive small cell lung cancer.(2)
0
Mostrar mas Mensajes
